These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31830465)

  • 1. Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor.
    Kiriakidi S; Chatzigiannis C; Papaemmanouil C; Tzakos AG; Mavromoustakos T
    Biochim Biophys Acta Biomembr; 2020 Mar; 1862(3):183142. PubMed ID: 31830465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan.
    Ntountaniotis D; Kellici T; Tzakos A; Kolokotroni P; Tselios T; Becker-Baldus J; Glaubitz C; Lin S; Makriyannis A; Mavromoustakos T
    Biochim Biophys Acta; 2014 Oct; 1838(10):2439-50. PubMed ID: 24946142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.
    Fotakis C; Megariotis G; Christodouleas D; Kritsi E; Zoumpoulakis P; Ntountaniotis D; Zervou M; Potamitis C; Hodzic A; Pabst G; Rappolt M; Mali G; Baldus J; Glaubitz C; Papadopoulos MG; Afantitis A; Melagraki G; Mavromoustakos T
    Biochim Biophys Acta; 2012 Dec; 1818(12):3107-20. PubMed ID: 22906712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.
    Ntountaniotis D; Andreadelis I; Kellici TF; Karageorgos V; Leonis G; Christodoulou E; Kiriakidi S; Becker-Baldus J; Stylos EK; Chatziathanasiadou MV; Chatzigiannis CM; Damalas DE; Aksoydan B; Javornik U; Valsami G; Glaubitz C; Durdagi S; Thomaidis NS; Kolocouris A; Plavec J; Tzakos AG; Liapakis G; Mavromoustakos T
    Mol Pharm; 2019 Mar; 16(3):1255-1271. PubMed ID: 30681344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative biophysical studies of sartan class drug molecules losartan and candesartan (CV-11974) with membrane bilayers.
    Fotakis C; Christodouleas D; Zoumpoulakis P; Kritsi E; Benetis NP; Mavromoustakos T; Reis H; Gili A; Papadopoulos MG; Zervou M
    J Phys Chem B; 2011 May; 115(19):6180-92. PubMed ID: 21520922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach.
    Zervou M; Cournia Z; Potamitis C; Patargias G; Durdagi S; Grdadolnik SG; Mavromoustakos T
    Biochim Biophys Acta; 2014 Mar; 1838(3):1031-46. PubMed ID: 24374319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans.
    Vauquelin G; Fierens F; Van Liefde I
    J Hypertens Suppl; 2006 Mar; 24(1):S23-30. PubMed ID: 16601569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.
    Miura S; Okabe A; Matsuo Y; Karnik SS; Saku K
    Hypertens Res; 2013 Feb; 36(2):134-9. PubMed ID: 23034464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.
    Luo H; Wang X; Wang J; Chen C; Wang N; Xu Z; Chen S; Zeng C
    Cardiovasc Diabetol; 2015 Jun; 14():76. PubMed ID: 26055622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do all angiotensin II type 1 receptor blockers have the same beneficial effects?
    Miura S; Saku K
    Br J Pharmacol; 2007 Aug; 151(7):912-3. PubMed ID: 17572701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Arrestin-biased AT1R stimulation promotes extracellular matrix synthesis in renal fibrosis.
    Wang Y; Huang J; Liu X; Niu Y; Zhao L; Yu Y; Zhou L; Lu L; Yu C
    Am J Physiol Renal Physiol; 2017 Jul; 313(1):F1-F8. PubMed ID: 28274926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes.
    Larrayoz IM; Pang T; Benicky J; Pavel J; Sánchez-Lemus E; Saavedra JM
    J Hypertens; 2009 Dec; 27(12):2365-76. PubMed ID: 19730394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.
    Singh KD; Unal H; Desnoyer R; Karnik SS
    J Chem Inf Model; 2018 Jan; 58(1):182-193. PubMed ID: 29195045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist.
    Lochard N; Thibault G; Silversides DW; Touyz RM; Reudelhuber TL
    Circ Res; 2004 Jun; 94(11):1451-7. PubMed ID: 15117826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS.
    Oz H; Gavish D; Hass A; Shargorodsky M
    J Renin Angiotensin Aldosterone Syst; 2015 Sep; 16(3):547-52. PubMed ID: 25694056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurorestoration after traumatic brain injury through angiotensin II receptor blockage.
    Villapol S; Balarezo MG; Affram K; Saavedra JM; Symes AJ
    Brain; 2015 Nov; 138(Pt 11):3299-315. PubMed ID: 26115674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1 receptor blocker potentiates shear-stress induced nitric oxide production via modulation of eNOS phosphorylation of residues Thr(495) and Ser(1177.).
    Barauna VG; Mantuan PR; Magalhães FC; Campos LC; Krieger JE
    Biochem Biophys Res Commun; 2013 Nov; 441(4):713-9. PubMed ID: 24211212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay of cholesterol, membrane bilayers and the AT1R: A cholesterol consensus motif on AT1R is revealed.
    Kiriakidi S; Chatzigiannis C; Papaemmanouil C; Tzakos AG; Cournia Z; Mavromoustakos T
    Comput Struct Biotechnol J; 2021; 19():110-120. PubMed ID: 33384858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats.
    Zhou J; Pavel J; Macova M; Yu ZX; Imboden H; Ge L; Nishioku T; Dou J; Delgiacco E; Saavedra JM
    Stroke; 2006 May; 37(5):1271-6. PubMed ID: 16601219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.